Novo Nordisk raises 2026 outlook for third time on strong Wegovy pill sales
Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.
